

### Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. § 208(b)(3)

Wayne K. Goodman, M.D.


Committee: Psychopharmacologic Drugs Advisory Committee


Meeting Date: December 2, 2005

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to new drug application (NDA) 21-514, proposed trade name Methypatch (Methylphenidate Transdermal System, MTS), sponsored by Noven Pharmaceuticals, Inc., and Shire Pharmaceutical Group plc, proposed indication for the treatment of Attention Deficit Hyperactivity Disorder, I am eligible to receive a waiver under 18 U.S.C. § 208(b)(3).

Type of Interest	Nature	Magnitude
Employer's Contracts/Grants	Competitor	Between \$100,001 and \$300,000 per year.
Employer's Contract/Grant	Sponsor & Competitor	Less than \$100,000 per year.

I hereby request that FDA ~~make this information~~ publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

  
\_\_\_\_\_  
Signature of SGE

  
\_\_\_\_\_  
Date